Let's dissect the latest facts about the urinary incontinence therapeutics industry

The global urinary incontinence therapeutics market is expected to grow at a CAGR of more than 3% during the forecast
Urinary incontinence therapeutics industry growth is expected to accelerate massively over the next five years driven by the robust pipeline for the development of drugs for urinary incontinence treatment. Most of the urinary incontinence therapeutics that are currently in Phase III stage are likely to get approved during the forecast period to augment the growth of the global urinary incontinence therapeutics market. Furthermore, the increasing number of molecules being developed for urinary incontinence treatment will drive the demand for urinary incontinence therapeutics across the period of forecast. Technavio's urinary incontinence therapeutics industry analysis reveals promising markets around the world.
Want a bigger picture? Get a free sample of this report now!
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
The Americas will be the largest driver of growth for the global urinary incontinence therapeutics market
More than half of the incremental growth of the global urinary incontinence therapeutics market will be driven by the Americas during the forecast period, while EMEA and APAC are predicted to make sizeable contributions to the market growth. The Americas also held the largest share of around 52% in the global urinary incontinence therapeutics market, followed by EMEA and APAC respectively. However, APAC is forecasted to generate the fastest rate of growth in the global urinary incontinence therapeutics market over the next five years while the Americas will register a higher CAGR than EMEA during the same period.
Get more value with Technavio's subscription platform! Gain easy access to all Technavio's reports, along with on-demand services. Start your 14-day FREE trial
Allergan, Astellas Pharma, and Merck are among the leading vendors in the urinary incontinence therapeutics market
The global urinary incontinence therapeutics market is slated to become reasonably fragmented with the presence of several vendors who offer products for treatment for all types of urinary incontinence. Urinary incontinence is a widespread urological disorder affecting more than 200 million people worldwide and around 17 million people in the US. Many international and regional vendors are vying for their share of the global urinary incontinence therapeutics market, and players must differentiate themselves to gain vital traction over their peers.
This report offers a complete analysis of several companies, including:
- Allergan
- Astellas Pharma
- Merck
- Novartis
- Pfizer
Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements. Get in touch
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Anticholinergic drugs - Market size and forecast 2018-2023
- Others - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- ALLERGAN
- Astellas Pharma
- Merck
- Novartis
- Pfizer
PART 14: APPENDIX
- Research methodology
- List of abbreviations
PART 15: EXPLORE TECHNAVIO
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape